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Background. Live oral cholera vaccines may protect against cholera in a manner similar to natural cholera
infections. However, information on which to base these vaccines is limited.
Methods. The study was conducted in a cholera-endemic population in Bangladesh. Patients with cholera
(index patients) detected between 1991 and 2000 were age-matched to 4 cholera-free controls and then followed up
during the subsequent 3 years.
Results. El Tor cholera was associated with a 65% (95% confidence interval [CI], 37%–81%; P , .001) lower
risk of a subsequent El Tor episode. Reduction of the risk of subsequent El Tor cholera was similar for children
,5 years and for older persons and was sustained during all 3 years of follow-up. Having El Tor Inaba cholera was
associated with lower risks of both El Tor Inaba and El Tor Ogawa cholera, but having El Tor Ogawa cholera was
associated only with a reduced risk of El Tor Ogawa cholera. O139 cholera was associated with a 63% (95% CI,
261% to 92%; P 5 .18) lower risk of subsequent O139 cholera, but there was no evidence of cross-protection
between the O1 and O139 serogroups.
Conclusions. Live oral cholera vaccines designed to protect against the O1 and O139 serogroups should contain
at least the Inaba serotype and strains of both serogroups.
Vibrio cholerae serogroup O1 and O139 organisms cause
acute, watery diarrhea, with an estimated 100 000–
150 000 deaths annually, and both endemic and epi-
demic disease [1]. There are 2 biotypes of V. cholerae O1
organisms, classical and El Tor. Based on differences in
antigenic determinants of the lipopolysaccharide O an-
tigen, the biotypes are further subclassified into Inaba
and Ogawa serotypes. The current (seventh) pandemic
of cholera is caused by V. cholerae O1, El Tor biotype.
V. cholerae O139, newly emerged in 1992 [2, 3]. After its
emergence, V. cholerae O139 predominated for a time as
the cause of clinical cholera in areas of Asia but was
eventually largely replaced by El Tor cholera.
Despite global efforts to improve drinking water
quality and sanitation in developing countries, there has
been little evidence of a decline in the global burden of
cholera in recent years. Interest has therefore increased
in the use of cholera vaccines as adjuncts to other pre-
ventive and therapeutic measures. Modern approaches
to creating cholera vaccines have focused primarily on
orally delivered vaccines, either with inactivated or live
antigens, the latter typically consisting of genetically
attenuated cholera strains.
Live oral cholera vaccines have the theoretical ad-
vantage of simulating infection by natural cholera. Ex-
perimental infection of North American volunteers has
been shown to protect against cholera upon rechallenge,
raising the possibility that live oral vaccines may be
protective after single-dose regimens. This expectation
has been borne out for several live oral vaccines tested in
challenge studies in North American volunteers [4–7].
However, to date no live oral vaccine has conferred
protection to cholera-endemic populations when tested
in a randomized trial, suggesting that the predictions
from studies of volunteers lacking preexisting immunity
to cholera may not be readily generalizable to cholera-
endemic populations.
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One way to estimate the level of protection potentially
achievable by live oral cholera vaccines in cholera-endemic
populations is to study the protection conferred by natural
cholera infections in these populations. Several cohort studies of
this type have been conducted in the past [8–10]. None was
designed to evaluate the comparative protection conferred
by O1 and O139 infections studied concurrently, nor cross-
protection conferred by the 2 El Tor serotypes—Inaba and
Ogawa—against one another, and none evaluated the protection
conferred by natural cholera in young children vs older persons,
nor the duration of natural protection. In this paper, we report




The study was conducted in Matlab, a research site of the In-
ternational Centre for Diarrhoeal Disease Research, Bangladesh
(ICDDR,B) with endemic cholera documented over several
decades. The site is approximately 50 km southeast of Dhaka, the
capital of Bangladesh. The study area is 184 km2, which is
bisected by the Dhonagoda River into almost 2 equal portions.
About 85% of the population is Muslim. It is a densely pop-
ulated area with about 1000 people per square kilometer, and
a total population of about 200 000 [9]. Like other rural areas of
Bangladesh, educational attainment is low.
Initiated in 1966, the Matlab health and demographic sur-
veillance system keeps reliable records of all vital demographic
events of the study area population [11, 12]. Each individual is
identified by a registration number given by the surveillance
system. In Matlab people live in groups of patrilineally linked
households sharing a courtyard, called baris. In 1996 a bari-level
geographic information system (GIS) was created that maintains
the temporal sequence of locations of all baris ever registered in
the surveillance system. The GIS also contains other important
features such as rivers, roads, and hospitals in the study area. For
the period for this study, 1 January 1988–31 December 2003,
demographic and geographic data were arranged into a linked
dynamic population database.
Surveillance for cholera was conducted during the study pe-
riod in the ICDDR,B hospital in Matlab. During the period
1988–1990, surveillance was also conducted in 2 community
diarrheal treatment centers, that had been established for a field
trial of killed oral cholera vaccines [13]. However, the surveil-
lance in these treatment centers was discontinued after the trial
was over in 1990. In all 3 of these treatment settings, all patients
presenting with diarrhea were clinically evaluated and treated.
For those residing in the ICDDR,B study area, fecal samples were
collected and evaluated for V. cholerae, by serogroup, biotype,
and serotype, using conventional microbiological methods
[14, 15]. All patient services in these facilities were free of charge,
and there was a free boat service for patients who needed to be
transported for care on an emergency basis. Therefore, it can
reasonably be assumed that the surveillance captured virtually
all clinically significant cholera cases among residents of the
ICDDR,B study area.
Selection of Cholera Index Patients and Controls
In this study, we compared 2 cohorts, 1 consisting of cholera
index patients and the other consisting of noncholera controls,
for the occurrence of cholera during the 3 years following se-
lection. Cholera was defined as an illness in which the patient
complained of diarrhea and in which a fecal specimen yielded
V. cholerae O1 or O139. The date of presentation for care was
taken as the date of selection for the index patient and 4 controls
matched to the index patient.
To select index patients, we first assembled all treatment visits
for cholera during the period 1 January 1988–31 December
2003. Beginning with a date of selection of 1 January 1991 and
proceeding forward in time, we included all cases meeting the
following criteria: (1) the patient had resided in Matlab during
the 3 years before selection and there was no history of cholera
during that interval or, (2) for patients ,3 years of age on the
date of selection, the patient had resided in Matlab since birth
and had no history of cholera from birth until the date of se-
lection. We excluded as an index patient anyone whose treat-
ment visit for cholera occured in an earlier selected control for
which the date of presentation for care was within 3 years fol-
lowing the date of selection of the control (vide infra). This
selection process yielded 4657 index patients.
For each selected index patient, we selected 4 age-matched
controls without cholera. To select controls, we first arranged
the selected index patients in temporal order according to the
date of selection. Then, beginning with the earliest selected index
patient, we sequentially selected 4 randomly sampled persons
who were residents of Matlab on the date of selection for the
matched index patient and who (1) were the same age (in years)
as the index patient on the date of selection; (2) did not reside in
the same bari as the matched index patient on the date of se-
lection; and (3) had resided in Matlab during the 3 years before
selection and had no history of cholera during that interval, or, if
,3 years of age on the date of selection, had resided in Matlab
since birth and had no history of cholera from birth until the
date of selection. This process yielded 18 628 matched controls.
Analytic Methods
We used survival analysis to compare cohorts of index cholera
patients and controls for the occurrence of subsequent cholera
[16–18]. We fitted a proportional hazards model to evaluate the
association between a clinical episode of cholera and the sub-
sequent occurrence of cholera. These models assessed the time to
presentation for care of the first episode of cholera in which the
date of presentation was between the day of selection for the
index patients and matched controls and 3 years (1095 days)
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thereafter, treating deaths and outmigrations as censoring
events. We fitted both unadjusted and covariate-adjusted mod-
els. In unadjusted models, the only independent variable was
a cohort identity variable (index patient vs control). Adjusted
models included as independent variables age, the matching
variable (age at selection), as well as demographic variables
known to be associated with the risk of treated cholera in
Matlab, including gender, religion, distance from household to
hospital, and distance from residence to the Dhonagoda River
[8, 11]. To avoid overfitting these models, we selected a maxi-
mum of 1 independent variable per 10 outcome events, se-
lecting those variables that had the lowest P values for the
association with the time to the occurrence of cholera in bi-
variate analyses. Hazard ratios (HRs) for the occurrence of
cholera in index patients vs controls were estimated by ex-
ponentiating the coefficient for the cohort identity variable
(index vs control) in these models, and the protection (PE)
against recurrent cholera was estimated as [(12HR) 3 100%].
Standard errors for the coefficients were used to estimate 2-
tailed P values and confidence intervals (CIs) for the HRs.
When models failed to converge, we calculated protection as
a crude incidence rate ratio, and used Kaplan–Meier survival
curves with the log-rank test to estimate P values for the
compared curves.
RESULTS
We assembled 4657 index cholera patients and 18,628 controls
during the period 1991–2000. Twenty-nine percent of the epi-
sodes were in children ,5 years of age, 27% were in persons
5–14 years of age, and 44% were in persons aged $15 years.
El Tor was the dominant strain (73%), followed by V. cholerae
O139 (27%). Classical cholera was detected in 26 index patients.
In the index patient and control cohorts, only 9% (2013 of
23 285) of subjects died or outmigrated before completion of the
third year of follow-up. In total, 211 subsequent cases of cholera
were detected among these index patients and their controls.
The baseline characteristics of the cohorts on the date of se-
lection are shown in Table 1. Except for the matching variable
(age), other variables showed a significant imbalance (P , .01)
between index patients and their controls. In all 26 index pa-
tients with classical cholera, detection occurred at the beginning
of the study period, and no subsequent cases of cholera were
observed among these index patients or their matched controls.
As shown in Table 2, 12 cases of El Tor were observed among
El Tor index patients (1.2 cases per 1000 person-years [py]), and
111 were detected among their matched controls (2.9 cases per
1000 py; adjusted PE, 65%; 95% CI, 37%–81%; P , .001). Two
cases of O139 cholera were observed among subjects with index
episodes of O139 cholera (0.6 cases per 1000 py) as opposed to
18 cases of O139 cholera among controls (1.3 cases per 1000 py;
adjusted PE, 63%; 95% CI, 261% to 92%; P 5 .18). There was
no evidence of serogroup-heterologous protection conferred by
index episodes of El Tor or O139 cholera (adjusted PE, 240%;
95% CI, 2138% to 17%; P 5 .21).
Age-specific analyses of biotype-homologous protection as-
sociated with El Tor cholera (Table 3) found an adjusted PE of
66% (95% CI, 29%–84%; P , .01) for children infected at
,5 years of age and 65% (95% CI 0%–88%; P 5 .05) for older
persons. As shown in Table 4, among index patients with El
Tor Inaba cholera and their controls, there were 0 and 4 cases,
respectively, of subsequent El Tor Inaba cholera (PE, 100%;
P 5 .32 in unadjusted analysis). Correspondingly there were
7 and 70 cases of El Tor Ogawa detected among El Tor Ogawa
index patients and their controls, respectively, yielding an ad-
justed PE of 69% (95% CI, 32%–86%; P , .01). Among index
patients with El Tor Inaba cholera and their controls, there were
0 and 17 cases, respectively, of El Tor Ogawa cholera (PE, 100%;
P 5 .04 in unadjusted analysis). In contrast, the incidence of El
Tor Inaba cholera in the El Tor Ogawa index patients and their
controls was identical (0.6 cases per 1000 py), yielding an ad-
justed PE of –1% (95% CI, 2170% to 62%; P 5 .98).
As shown in Table 5, when examined by the time after se-
lection, biotype-homologous protection associated with El Tor
cholera was 62% (95% CI, 11%–84%; P 5 .02) during the first
year after selection, 68% (95% CI, 9%–89%; P5.03) during the
second year, and 72% (95% CI, 222% to 94%, P5 .09) during
the third year.
DISCUSSION
Our findings indicate that index episodes of El Tor cholera were
associated with a moderate (65%) reduction of the risk of
subsequent El Tor cholera, that this protection was evident both
in young children and in older persons, and that the protection
showed no evidence of decline over a 3-year period of follow-up.
Protection associated with El Tor infection appeared to differ by
the serotype of the infection. Inaba infections showed clear ev-
idence of protection against Ogawa infections and apparent
protection against Inaba infections, though the latter was limited
by a small number of cholera outcomes. In contrast, Ogawa in-
fections were associated with protection only against the homol-
ogous serotype. Although not statistically significant, protection
associated with serogroup O139 cholera against cholera due to the
same serogroup was similar in magnitude (63%) to that associ-
ated with serogroup O1, El Tor biotype cholera. There was no
evident cross-protection between the O1 and O139 serogroups.
Strengths and Limitations of the Study
Before discussing the implications of these findings, it is im-
portant to point out several strengths and limitations of the
study. We excluded index patients and controls with episodes of
cholera during the 3 years prior to selection to help ensure that
measured levels of protection reflected the effect of the index
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episode per se. In addition, selection of index cholera patients
and detection of subsequent cholera among index patients and
their controls were based on comprehensive, population-based
surveillance for cholera, and there was very little loss to follow-
up among the cohort. However, it is possible that our estimates
of protection were made conservative by the possibility that
index patients with cholera may have been more susceptible to
cholera than their matched controls or may have been more
likely than their matched controls to have sought care for
cholera. We attempted to control for these biases by adjusting
for potential confounding variables as well as the distance of the
subject’s residence to the hospital where cholera was detected.
On the other hand, all index cholera infections under study were
clinically severe enough to prompt solicitation of treatment.
Because these clinically severe infections were likely to have
elicited more robust immune responses than clinically mild
infections, which might more closely correspond to the im-
munogenic stimulus of a nonreactogenic oral cholera vaccine,
the analysis could have overestimated the level of protection to
be expected of live oral vaccines in endemic populations. Finally,
the study was not of adequate size to evaluate with suitable
precision protection in all subgroups of interest, including in-
fection and reinfection by 0139 cholera, which did not occur
with a high frequency throughout the study interval.
Relation to Other Studies
Past cohort studies of the protection conferred by natural
cholera infection have yielded widely disparate estimates, rang-
ing from nil to .90% [8–10]. The 1 study finding no protection
included mild or asymptomatic cholera infections, which, as
Table 1. Features of Index Patients and Controls
Variable Index patients (n 5 4657) Controls (n 5 18 628) P valuea
Age category
,5 years 1354 (29%) 5416 (29%) 1.00
5–14 years 1269 (27%) 5076 (27%)
$15 years 2034 (44%) 8136 (44%)
Age (years)b 20.18 (21.04) 20.18 (20.04) 1.00
Gender
Male 2318 (50%) 9931 (53%) ,.001
Female 2339 (50%) 8697 (47%)
Religion
Muslim 4299 (92%) 16 241 (87%) ,.001
Hindu 358 (8%) 2387 (13%)
Distance from residence to hospital (km)b 4.62 (2.40) 6.52 (3.84) ,.001
Distance from residence to Dhonagoda River (km)b 1.25 (0.99) 1.32 (1.17) .001
Duration of postselection follow-up (days)b 1041 (200) 1043 (192) .50
NOTE. a The P values were obtained from the v2 test for categorical variables and from the Student t test for continuous variables.
b Mean and standard deviations (in parentheses) are shown for these variables.
Table 2. Cholera Episodes Among El Tor and 0139 Index Patients and Controls During 3 Years of Follow-up, Matlab, Bangladesh
Serogroup- and biotype-homologous
index and outcome strains
Serogroup- heterologous index and
outcome strains













Number of index patients
and matched controls
3394 13 576 1237 4948 4631 18 524
Number of cholera episodes
detected during follow-up
12 111 2 18 20 48
Person-days of follow-up 3 531 226 14 199 959 1 297 577 5 153 838 4 828 070 19 402 067
Incidence (per 1000 person-years) 1.2 2.9 0.6 1.3 1.5 0.9
Protection (95% CI; P value)
Unadjusted analysis 56% (20%–70%; ,.01) 56% (290% to 90%; .27) 268% (2183% to 1%; .052)
Adjusted analysis 65% (37%–81%; ,.001)a 63% (261% to 92%; .18)b 240% (2138% to 17%, .21)a
NOTE. a Adjusted for age, gender, religion, distance from residence to hospital, and distance from residence to Dhonagoda River.
b Adjusted for age and distance from residence to hospital.
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noted earlier, may be associated with less robust induction of
protective immunity than cholera severe enough to require
treatment; all other studies have focused on more severe cholera.
Our study found no subsequent episodes of cholera among in-
dex patients with classical cholera. Although interpretation of
this finding is limited by the absence of cholera in the controls
matched to these classical cholera index patients, it is nonethe-
less interesting that an earlier study done in Bangladesh found
that episodes of classical cholera were associated with complete
protection against recurrent cholera [9]. However, neither study
had sufficient power to be able to state that the protection by
classical cholera is serotype-independent.
Biological Implications
Demonstration of protection by episodes of O1 and O139 cholera
against the infection by the same serogroup, as well as the absence
of cross-protection between the O1 and O139 serogroups, was
expected based on earlier studies [19–21] and the known struc-
tural differences of the O antigen of these 2 serogroups. In-
terestingly, protection by Inaba antigen against both Inaba and
Ogawa cholera, but protection by Ogawa antigen only against
Ogawa cholera, was observed for parenteral cholera vaccines
tested decades ago, and an analysis of trends of cholera in
Bangladesh over a 33-year period suggested that Inaba cholera
confers greater protection than Ogawa cholera [22–24]. However,
to our knowledge, the results of this study are the first to confirm
these relationships for natural cholera infections. The Ogawa and
Inaba serotypes differ only by a 2-O-methyl group that is present
in the nonreducing terminal sugar of the Ogawa O-specific
polysaccharide (O-SP) of V. cholerae lipopolysaccharide but is
absent in the Inaba O-SP [25–27]. It is likely that the effect of
these structural determinants on protective epitopes provides the
basis for our observations on homologous vs heterologous pro-
tection elicited by infections by these 2 serotypes. Secular changes
Table 3. El Tor Cholera Episodes Among El Tor Index Patients and Matched Controls During 3 Years of Follow-up by Age Group, Matlab,
Bangladesh
Age ,5 years at selection Age $5 years at selection
Index patients Matched controls Index patients Matched controls
Number of index patients and matched controls 1165 4660 2229 8916
Number of cholera episodes detected during follow-up 8 75 4 36
Person-days of follow-up 1 188 820 4 849 670 2 342 406 9 350 289
Incidence (per 1000 person-years) 2.5 5.6 0.6 1.4
Protection (95% CI; P value)
Unadjusted analysis 56% (10%–79%; .02) 56% (225% to 84%; .12)
Adjusted analysis 66% (29%–84%; ,.01)a 65% (0%–88%; .05)b
NOTE. a Adjusted for age, gender, religion, distance from residence to hospital, and distance from residence to Dhonagoda River.
b Adjusted for age, gender, and distance from residence to hospital.
Table 4. El Tor Cholera Episodes Among El Tor Index Patients and Controls by Serotype of the Index and Outcome Infections During 3
Years of Follow-up, Matlab, Bangladesh
Serotype of outcome infection
homologous to that for index patient
Serotype of outcome infection heterologous
to that for index patient



















546 2184 2848 11 392 546 2184 2848 11 392
Number of cholera episodes
detected during follow-up
0 4 7 70 0 17 5 20
Person-days of follow-up 565 754 2 297 598 2 968 005 11 923 054 565 754 2 289 554 2 970 926 11 958 055
Incidence
(per 1000 person-years)
0.00 0.6 0.9 2.1 0.00 2.7 0.6 0.6
Protection (95% CI; P value)
Unadjusted analysis 100% (not applicable; .32)a 60% (13%–82%; .02) 100% (not applicable; .04)a 0% (2168% to 62%; 0.99)
Adjusted analysis 100% (not applicable; .32)a 69% (32%–86%; ,.01)a 100% (not applicable; .04)a 21% (2170% to 62%; .98)b
NOTE. Models did not converge, and 95% confidence interval (CI) was not estimable. P value was estimated using the log-rank test for Kaplan–Meier curves.
a Adjusted for age, gender, religion, distance from residence to hospital, and distance from residence to Dhonagoda River.
b Adjusted for age.
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in prevailing serotypes are frequently observed in cholera-
endemic populations, more frequently from Ogawa to Inaba than
the reverse. The role of serotype-specific immunity, homologous
and heterologous induced by Inaba vs homologous only for
Ogawa, in influencing these switches remains to be determined.
Practical Implications
Our findings have several implications for the design, de-
velopment, and evaluation of live oral vaccines against cholera.
They also inform the development of future inactivated oral
vaccines against cholera. First, although our data support the
immunizing potential of both El Tor and O139 vaccine strains,
they are cautionary in the sense that they suggest that the upper
limit of protective efficacy that can be expected of these strains
may be moderate in magnitude. Second, these moderate levels of
protection contrast with the high levels of protection seen in
nonimmune North American volunteers participating in studies
of the protection conferred against cholera challenges by wild-
type cholera infections and by live oral vaccine candidates, un-
derscoring the limitations of the North American cholera chal-
lenge model in predicting vaccine performance in populations
with endemic cholera. Third, if protection is desired against both
El Tor and O139 cholera, vaccines will have to be at least bivalent
with respect to the serogroups of their constituent strains. Fi-
nally, for vaccine protection against El Tor Inaba cholera, an El
Tor Inaba vaccine strain will be needed; such a strain may also be
sufficient to protect against El Tor Ogawa cholera if a vaccine
parsimonious with respect to the number of strains is desired.
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